Search

everythinglearnresearchcommunity

for

Search:↓

Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

A new method accurately measures nine specific hormones in human blood.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

PCOS is linked to inflammation, and certain markers could help in its treatment.

Women with PCOS have a higher risk of heart disease due to factors like insulin resistance and obesity.

Patients with alopecia areata have higher oxidative stress and lower antioxidant levels.

Selenium supplements can help improve symptoms and metabolic markers in lupus patients.

High CRP levels could indicate vitamin D deficiency in people with alopecia areata.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Metformin improves early signs of heart disease in women with PCOS and raises apelin levels, but doesn't significantly change artery thickness.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Early recognition and treatment of Peripheral Arterial Disease is crucial to improve survival and health outcomes.

MX1 and AR genes are linked to milder COVID-19, while TMPRSS2 increases severe risk, especially in women.

A 44-year-old woman with Down's syndrome was diagnosed with both rheumatoid and gouty arthritis and treated with multiple medications.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Analog 23 is a promising compound for prostate cancer treatment.

COVID-19 leaves 80% of patients with long-term symptoms like fatigue and headaches.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Higher BMI may increase the risk of psoriasis and some other skin diseases.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.